Delhi, India-based biotechnology company Bioheaven360 Genotec Pvt Ltd raised approximately USD 122K (INR 1 crore) in recent funding. The company announced the fundraiser on January 16, 2023. Global community-backed angel network DFAN led the financing for the firm.
Purpose of financing for Bioheaven360 Genotec
With the latest funding from DFAN, the company intends to expand its facility and infrastructure for the production of medical devices.
Meanwhile, it has plans to continue the development of its innovative state-of-the-art products.
Moreover, Bioheaven360 Genotec aims to launch additional products in the microbiology and molecular domain later this year. Besides, it seeks to expand its reach across India and release it for testing the immuno-molecules.
What the company’s official has to say
Shailendra Vyas, PhD, Director of Bioheaven, said, “We are thrilled to receive this funding from DFAN. It will allow us to accelerate our growth and bring our innovative medical technologies to market. Moreover, it enables us to take significant steps towards achieving our long-term vision and short-term goals. We believe that our innovative approach to biotechnology will make a real difference in the lives of people suffering from critical diseases.”
What the investor has to add
Ganesh Viswanathan, Director of DFAN, further added, “As BioHeaven, a biotechnology start-up uses technology in their core business. Digital Futurists Angel Network (DFAN) has chosen to invest in this as we are part of the vision to leverage technology for effective and safe biotech. We are always looking for highly innovative, scalable solutions that can be adapted and scaled globally. With an increase in infectious pathogens, complicated regulatory oversight and increased need for state-of-the-art technology for high-quality products in diagnostics and therapeutics, DFAN is pleased to partner with BioHeaven, that has a strong presence in the growing market.”
About Bioheaven360 Genotec
Bioheaven360 Genotec Pvt Ltd is a Delhi-based biotechnology company pursuing scientific endeavours to develop next-generation diagnostics and immuno-therapies through Genomics, Recombinant DNA Technology, and AI for people suffering from acute diseases. The company’s long-term vision is to discover new cost-effective molecules for treating dreadful conditions as well as using AI-based data insights to enhance medical practices, predict risks early, and help people live longer, healthier lives. Bioheaven360 desires to become one of the biggest biotech companies in the world. With over 20 years of experience in the molecular biotechnology and in-vitro diagnostic industries, Bioheaven360 is a trusted name in the healthcare industry.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
 in recent funding.){kind=link}